Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Recruiting, industry sponsors, Dermatology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed223
13 trials
Showing 1 to 13, recently updated first.
- Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)Pivotal-lookingRecruiting
Sagimet Biosciences Inc.Industry
NCT07863193 · 800 participants (planned) · Start Oct 21, 2026 · Primary completion Aug 2027
Drug: Denifanstat · For: Acne Vulgaris
Sites: Bryant, Arkansas; Beverly Hills, California; Fremont, California · 35 sites in all
- Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper ExtremitiesPivotal-lookingRecruiting
Sun Pharmaceutical Industries, Inc.Industry
NCT07144852 · 260 participants (planned) · Start Nov 29, 2025 · Primary completion Jan 2027
Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% · For: Actinic Keratosis
Sites: Phoenix, Arizona; Fremont, California; Castle Rock, Colorado · 22 sites in all
- Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and ScalpPivotal-lookingRecruiting
Sun Pharmaceutical Industries, Inc.Industry
NCT07144345 · 160 participants (planned) · Start Nov 19, 2025 · Primary completion Jan 2027
Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% · For: Actinic Keratosis
Sites: Fremont, California; Aventura, Florida; Rolling Meadows, Illinois · 12 sites in all
- Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne VulgarisPivotal-lookingRecruiting
Eurofarma Laboratorios S.A.Industry
NCT06905210 · 531 participants (planned) · Start Aug 24, 2026 · Primary completion Feb 2027
Drug: Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg); Placebo · For: Acne Vulgaris; Acne Vulgaris on the Face
Sites: Salvador, Brazil; Brasília, Brazil; Goiânia, Brazil · 18 sites in all
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis BullosaPivotal-lookingRecruiting
Paradigm TherapeuticsIndustry
NCT07482787 · 80 participants (planned) · Start Jul 21, 2026 · Primary completion May 17, 2027
Drug: SD-101 Dermal Cream (6%); Vehicle (SD-101 0%) · For: Epidermolysis Bullosa (EB)
Sites: Rancho Santa Margarita, California; Redwood City, California; Philadelphia, Pennsylvania · 4 sites in all
- Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT07538583 · 16 participants (planned) · Start Mar 19, 2026 · Primary completion Jan 31, 2027
Drug: QRX003 · For: Netherton Syndrome
Sites: Fremont, California; New Haven, Connecticut; Indianapolis, Indiana · 8 sites in all
- Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT06953466 · 8 participants (planned) · Start Oct 6, 2025 · Primary completion Dec 30, 2026
Drug: QRX003, 4% Lotion · For: Netherton Syndrome
Sites: Chicago, Illinois
- Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT05789056 · 20 participants (planned) · Start Mar 14, 2023 · Primary completion Dec 30, 2026
Drug: QRX003, 4% Lotion · For: Netherton Syndrome
Sites: San Diego, California; Indianapolis, Indiana; Quincy, Massachusetts · 4 sites in all
- A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaPivotal-lookingRecruiting
Krystal Biotech, Inc.Industry
NCT07016750 · 16 participants (planned) · Start Jun 20, 2025 · Primary completion Dec 2026
Drug: KB803; Placebo · For: Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa and 1 more
Sites: Rancho Santa Margarita, California; Coral Gables, Florida; Worcester, Massachusetts · 5 sites in all
- A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis BullosaPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06917690 · 6 participants (planned) · Start Apr 18, 2025 · Primary completion Mar 2026
Drug: Oleogel-S10 · For: Epidermolysis Bullosa; Junctional Epidermolysis Bullosa; Epidermolysis Bullosa, Dystrophic and 7 more
Sites: Fukuoka, Japan; Kobe, Japan; Niigata, Japan · 6 sites in all
- Saccharomyces Boulardii CNCM I-745 in Irritable Bowel SyndromePivotal-lookingRecruiting
BiocodexIndustry
NCT07168434 · 406 participants (planned) · Start Oct 22, 2025 · Primary completion Oct 11, 2026
Drug: Saccharomyces Boulardii 250 MG; Placebo 250 mg · For: IBS (Irritable Bowel Syndrome); IBS-D (Diarrhea-predominant); IBS, Mixed Symptoms
Sites: Braga, Portugal; Lisbon, Portugal; Barcelona, Spain · 10 sites in all
- Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic KeratosisPivotal-lookingRecruiting
Aresus Pharma GmbHIndustry
NCT07137819 · 280 participants (planned) · Start Sep 4, 2024 · Primary completion Mar 2026
Drug: Topical treatment · For: Actinic Keratosis of Face and Scalp
Sites: Strausberg, Germany
- Efficacy and Safety of Clascoterone Cream 1% in Facial Acne VulgarisPivotal-lookingRecruiting
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Industry
NCT06403501 · 692 participants (planned) · Start May 20, 2024 · Primary completion Oct 2026
Drug: Clascoterone; Vehicle cream · For: Acne Vulgaris
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.